review · Discover Bacteria.
Colistin is a last-resort antibiotic for multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa infections; however, colistin-resistance is rising globally. This study synthesizes global data on colistin-resistance mechanisms, high-risk clones (HRCs), and One Health dynamics. This study screened 1318 records and analyzed 40 studies using PRISMA guidelines. The literature search was conducted from March 01 and April 30, 2025. Data extraction covered colistin-resistance genes, sequence types (STs), and co-resistance patterns. The results reveal that colistin resistance is primarily driven by chromosomal mutations (in pmrAB and phoPQ) and plasmid-borne mcr genes with high detection of mcr-1. HRCs were dominant globally, and most colistin-resistant isolates exhibited co-resistance to β-lactams/carbapenems, amplifying MDR/XDR threats. Resistance rates showed regional heterogeneity in Asia, Europe, and America compared to Africa and the Middle East. The study suggests that regulated colistin use, enhanced genomic surveillance, regular antibiotic stewardship programs, development of rapid diagnostics and novel therapies are necessary to combat the spread of MDR/XDR P. aeruginosa strains.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s44351-026-00044-y
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.